Fertility Preservation in Female Cancer Patients

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left"> High risk</td><td align="left">Cyclophosphamide, ifosfamide, nitrosoureas, busulfan, chlorambucil, melphalan, procarbazine</td></tr><tr><td align="left">Intermediate risk</td><td align="left">Cisplatin, adriamycin</td></tr><tr><td align="left">Low or no risk</td><td align="left">Methotrexate, fluorouracil, vincristine bleomycin, dactinomycin</td></tr><tr><td align="left">Unknown risk</td><td align="left">Taxanes, oxaliplatin, irinotecan, monoclonal antibodies, tyrosine kinase inhibitors</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Risks of gonadotoxicity in different chemotherapeutic agents.

International Scholarly Research Notices

tab1

Table 1

Table 1: Fertility Preservation in Female Cancer Patients 